Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
Guest post by L. Michelle Bennett, director of the NCI Center for Research Strategies; Worta McCaskill-Stevens, MD, chief of...
The flurry of anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) late last month included the...
Kimberly Stegmaier, MD, co-director of the pediatric hematologic malignancy program and associate professor of pediatrics at Dana-Farber Cancer Institute...
Guest Post by Charles L. Sawyers, MD AACR Project GENIE Steering Committee Chairperson
Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov....
Guest Post by Varsha Gandhi, PhD The University of Texas MD Anderson Cancer Center
Carlos L. Arteaga, MD, past-president of the AACR, has been selected to receive the 2015 Prize for Scientific Excellence...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a first-of-its kind immunotherapeutic, talimogene laherparepvec or T-Vec...
After being diagnosed with stage 4 stomach cancer, Debbie Zelman, Esq., started Debbie’s Dream Foundation: Curing Stomach Cancer (DDF)...
Eddy Shih-Hsin Yang, MD, PhD, associate professor and Regional Oncology Active Research (ROAR) Southeast Cancer Foundation Endowed Chair at...